

28 February 2025

ISSUE OF CONVERTING NOTES

Holista Colltech Limited (ASX: HCT) (Holista or the Company) is pleased to announce significant financial developments involving converting note issuance that further solidify the Company's financial base and bolster confidence in our future operations.

The Company has negotiated the issuance of two converting notes totalling USD600,000 and AUD600,000 respectively under listing Rule 7.1 capacity¹. Raising a total of approximately AUD1,545,100.

This strategic issuance is designed to support the Company's ongoing growth initiatives and to repay the outstanding ASIC obligations, ensuring our commitment to regulatory compliance and continued financial health.

Detailed terms of the Converting Notes are located in Annexure 1.

Converting Note 1.

Counterpart: Mr Greg Pilant or Nominee

Investment Value: USD600,000

Maturity Date: 30th June 2025

Conversion Price: AUD 0.0315 per share

Conversion: Notes to convert into ordinary shares of Holista Colltech Limited at any time prior to maturity at the conversion price, subject to the terms and conditions of the conversion.

An additional condition that Greg has requested is a seat the board of Holista Colltech for a nominal Directors fee of A\$1.00 per annum.

Mr Pilant is the founder, CEO, and Chairman of Regenerex Pharma, Inc., which is listed on the OTCB in the United States as well as several other private companies. A lifelong entrepreneur, he established Greystone Pharmaceuticals, Inc., and has led various medical and pharmaceutical firms since 1985, including Stanley Pharmaceuticals, National Labs, and MedStat.

With over 30 years of experience in wound care, Mr. Pilant has been instrumental in setting up manufacturing facilities across the United States, China, Europe, and the Middle East. His expertise spans FDA and CE compliance, reimbursement, manufacturing, and distribution. Notably, he was among the first fifteen individuals inducted into the University of Memphis Business Hall of Fame.

Converting Note 2

- **Counterpart:** Mr Tee Kian Heng or Nominee
- **Face Value:** AUD600,000
- **Maturity Date:** 30th June 2025
- **Conversion Price:** \$0.0315 per share
- **Conversion:** Notes to convert into ordinary shares of Holista Colltech Limited at any time prior to maturity at the conversion price, subject to the terms and conditions of the conversion.

Tee Kian Heng is a Malaysian entrepreneur who is active in the timber, real estate and property businesses. He is a long term strategic investor and now looking increasingly invest in the healthcare space. Mr. Tee currently holds 1,482,459 Ordinary shares in HCT.

Use of Funds

The funds raised through the Converting Notes will be strategically allocated to enhance our working capital capability and to facilitate the repayment of the remaining ASIC debt. This capital inflow not only strengthens our financial position but also aligns with our goals of upholding the highest standards of corporate governance.

Board and Management's Commitment

The Board, including non-executive chairman David Deloub, and the management team extend their gratitude to Mr. Pilant and Mr. Tee for their significant financial contributions and ongoing support.

The company also welcomes Mr Greg Pilant to the board with his depth of experience and breadth of expertise. These actions underscore a robust commitment to Holista's long-term success and stability in the healthcare space.

Looking Forward

Holista continues to focus on its core mission of developing natural solutions that promote healthier living. With a strengthened financial foundation and continued support from our directors, Holista is well-positioned to pursue its strategic goals and expand its impact in the health solutions market globally.

This release has been approved by the Board of Directors.

-- ENDS --

¹ LR 7.1 Shareholder approval is required for a portion of the shares on conversion. Refer to Annexure 1 for details.

ABOUT HOLISTA COLLTECH

Holista Colltech Ltd (**Holista**) is a research-driven biotech company, a result of the merger of Holista Biotech Sdn Bhd and Colltech Australia Ltd. It is listed on the Australian Securities Exchange (**ASX:HCT**), headquartered in Perth and has extensive operations in multiple countries, including Malaysia and North America.

Holista's core business is to conduct research to find natural solutions so that people can live healthier lives. The Group holds proprietary solutions to help food manufacturers produce healthier alternatives – without use of chemicals – that do not compromise tastes and mouthfeel. Building on its partnership network and expertise, Holista has also developed sanitising solutions for individual and corporate use to control pandemic infections.

Annexure 1: Key Terms of Financial Instruments**1. Converting Note 1 :**

- **Issuer:** Holista Colltech Limited
- **Subscriber:** Mr Greg Pilant or Nominee
- **Investment Amount:** USD600,000
- **Face Value of notes:** AUD1.00 each
- **Number of Convertible Notes:** ~945,000
- **Conversion Price:** AUD0.0315 per share
- **Maturity Date:** June 30th 2025
- **Security:** Unsecured
- **Conversion:** Notes to convert into ordinary shares of Holista Colltech Limited at any time prior to maturity at the conversion price, subject to the terms and conditions of the conversion.
- **Voting Rights:** None until conversion
- **Listing:** The converting notes are not quoted on the ASX or any other financial market.
- **Additional condition :** HCT Board membership
- **Shareholder approval:** Shareholder approval is not required for the conversion to ~30,000,000 Shares

2. Converting Note 2 :

- **Issuer:** Holista Colltech Limited
- **Subscriber:** Tee Kian Heng
- **Investment Amount:** AUD600,000
- **Face Value:** AUD1.00 each
- **Conversion Price:** AUD0.0315 per share
- **Maturity Date:** June 30th 2025
- **Security:** Unsecured
- **Conversion:** Note to convert into ordinary shares of Holista Colltech Limited at any time prior to maturity at the conversion price, subject to the terms and conditions of the conversion.
- **Voting Rights:** None until conversion
- **Listing:** The converting notes are not quoted on the ASX or any other financial market.
- **Shareholder Approval:** The Notes will convert into 19,047,619 Shares. 6,297,619 of these share will only be issued upon receiving Shareholder approval.